Product Description
Mechanisms of Action: H2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Bangladesh | India | Ireland | Italy | Japan | Korea | Portugal | South Africa | Taiwan | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Sihuan Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20200196 | N/A |
Completed |
Edema|Gastritis|Duodenal Ulcer|Zollinger-Ellison Syndrome|Duodenal Diseases|Esophagitis |
2020-09-04 |
|
CTR20190618 | N/A |
Completed |
Duodenal Ulcer|Esophagitis|Duodenal Diseases|Edema|Gastritis |
2019-05-08 |